Cellectar Biosciences Past Earnings Performance
Past criteria checks 0/6
Cellectar Biosciences's earnings have been declining at an average annual rate of -30.2%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-30.2%
Earnings growth rate
43.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -302.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully
Aug 08
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Feb 12Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
Aug 23Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19
Aug 05Cellectar announces reverse stock split
Jul 21We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
May 10Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
Jan 20Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?
Oct 05Cellectar shares fall after mid-stage CLR 131 trial data fails to impress
Jun 04We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely
May 20Cellectar Biosciences EPS beats by $0.03
May 10Cellectar gets notification of formal grant from Australian and Mexican patent authorities
Apr 27Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer
Jan 12Cellectar Bio readies stock offering
Dec 23We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
Nov 30
Cellectar Biosciences EPS beats by $0.05
Nov 09Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors
Nov 05Revenue & Expenses Breakdown
How Cellectar Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -50 | 24 | 28 |
| 30 Jun 24 | 0 | -53 | 18 | 29 |
| 31 Mar 24 | 0 | -62 | 14 | 28 |
| 31 Dec 23 | 0 | -43 | 12 | 27 |
| 30 Sep 23 | 0 | -42 | 10 | 24 |
| 30 Jun 23 | 0 | -36 | 10 | 22 |
| 31 Mar 23 | 0 | -33 | 11 | 21 |
| 31 Dec 22 | 0 | -32 | 11 | 18 |
| 30 Sep 22 | 0 | -27 | 9 | 18 |
| 30 Jun 22 | 0 | -25 | 9 | 17 |
| 31 Mar 22 | 0 | -24 | 7 | 17 |
| 31 Dec 21 | 0 | -24 | 7 | 18 |
| 30 Sep 21 | 0 | -22 | 6 | 16 |
| 30 Jun 21 | 0 | -20 | 6 | 14 |
| 31 Mar 21 | 0 | -17 | 6 | 12 |
| 31 Dec 20 | 0 | -15 | 5 | 10 |
| 30 Sep 20 | 0 | -15 | 5 | 10 |
| 30 Jun 20 | 0 | -15 | 5 | 10 |
| 31 Mar 20 | 0 | -14 | 5 | 9 |
| 31 Dec 19 | 0 | -14 | 5 | 9 |
| 30 Sep 19 | 0 | -15 | 5 | 8 |
| 30 Jun 19 | 0 | -16 | 5 | 7 |
| 31 Mar 19 | 0 | -16 | 5 | 7 |
| 31 Dec 18 | 0 | -15 | 5 | 7 |
| 30 Sep 18 | 0 | -17 | 5 | 9 |
| 30 Jun 18 | 0 | -15 | 5 | 9 |
| 31 Mar 18 | 0 | -16 | 5 | 10 |
| 31 Dec 17 | 0 | -15 | 4 | 9 |
| 30 Sep 17 | 0 | -15 | 4 | 8 |
| 30 Jun 17 | 0 | -14 | 4 | 7 |
| 31 Mar 17 | 0 | -13 | 5 | 6 |
| 31 Dec 16 | 0 | -9 | 5 | 5 |
| 30 Sep 16 | 0 | -3 | 4 | 4 |
| 30 Jun 16 | 0 | -2 | 4 | 4 |
| 31 Mar 16 | 0 | -2 | 3 | 5 |
| 31 Dec 15 | 0 | -5 | 3 | 5 |
| 30 Sep 15 | 0 | -10 | 3 | 6 |
| 30 Jun 15 | 0 | -8 | 3 | 6 |
| 31 Mar 15 | 0 | -7 | 4 | 6 |
| 31 Dec 14 | 0 | -8 | 4 | 6 |
| 30 Sep 14 | 0 | -9 | 4 | 6 |
| 30 Jun 14 | 0 | -10 | 4 | 7 |
| 31 Mar 14 | 0 | -10 | 4 | 7 |
Quality Earnings: CLRB is currently unprofitable.
Growing Profit Margin: CLRB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLRB is unprofitable, and losses have increased over the past 5 years at a rate of 30.2% per year.
Accelerating Growth: Unable to compare CLRB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLRB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CLRB has a negative Return on Equity (-302.82%), as it is currently unprofitable.